Literature DB >> 31504802

EANO guideline on the diagnosis and treatment of vestibular schwannoma.

Roland Goldbrunner1, Michael Weller2, Jean Regis3, Morten Lund-Johansen4, Pantelis Stavrinou1, David Reuss5, D Gareth Evans6, Florence Lefranc7, Kita Sallabanda8, Andrea Falini9, Patrick Axon10, Olivier Sterkers11, Laura Fariselli12, Wolfgang Wick13, Joerg-Christian Tonn14.   

Abstract

The level of evidence to provide treatment recommendations for vestibular schwannoma is low compared with other intracranial neoplasms. Therefore, the vestibular schwannoma task force of the European Association of Neuro-Oncology assessed the data available in the literature and composed a set of recommendations for health care professionals. The radiological diagnosis of vestibular schwannoma is made by magnetic resonance imaging. Histological verification of the diagnosis is not always required. Current treatment options include observation, surgical resection, fractionated radiotherapy, and radiosurgery. The choice of treatment depends on clinical presentation, tumor size, and expertise of the treating center. In small tumors, observation has to be weighed against radiosurgery, in large tumors surgical decompression is mandatory, potentially followed by fractionated radiotherapy or radiosurgery. Except for bevacizumab in neurofibromatosis type 2, there is no role for pharmacotherapy.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  diagnosis; radiotherapy; surgery; treatment; vestibular schwannoma

Year:  2020        PMID: 31504802      PMCID: PMC6954440          DOI: 10.1093/neuonc/noz153

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  174 in total

1.  Optimal extent of resection in vestibular schwannoma surgery: relationship to recurrence and facial nerve preservation.

Authors:  Ho Jun Seol; Choong-hyo Kim; Chul-Kee Park; Chi Heon Kim; Dong Gyu Kim; Young-Seob Chung; Hee-Won Jung
Journal:  Neurol Med Chir (Tokyo)       Date:  2006-04       Impact factor: 1.742

2.  Operative Mortality Rates of Acoustic Neuroma Surgery: A National Cancer Database Analysis.

Authors:  Shearwood McClelland; Ellen Kim; James D Murphy; Jerry J Jaboin
Journal:  Otol Neurotol       Date:  2017-06       Impact factor: 2.311

3.  Determinants of tumor size and growth in vestibular schwannomas.

Authors:  S L Nutik; M J Babb
Journal:  J Neurosurg       Date:  2001-06       Impact factor: 5.115

4.  The Risk of Radiation-Induced Tumors or Malignant Transformation After Single-Fraction Intracranial Radiosurgery: Results Based on a 25-Year Experience.

Authors:  Bruce E Pollock; Michael J Link; Scott L Stafford; Ian F Parney; Yolanda I Garces; Robert L Foote
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-01-09       Impact factor: 7.038

5.  Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma.

Authors:  D G Evans; R Lye; W Neary; G Black; T Strachan; A Wallace; R T Ramsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

6.  Assessment of internal auditory canal tumors: a comparison of contrast-enhanced T1-weighted and steady-state T2-weighted gradient-echo MR imaging.

Authors:  P Schmalbrock; D W Chakeres; J W Monroe; A Saraswat; B A Miles; D B Welling
Journal:  AJNR Am J Neuroradiol       Date:  1999-08       Impact factor: 3.825

7.  Genetic testing and screening of individuals at risk of NF2.

Authors:  D G Evans; F L Raymond; J G Barwell; D Halliday
Journal:  Clin Genet       Date:  2011-12-16       Impact factor: 4.438

8.  Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service.

Authors:  D G Evans; E Howard; C Giblin; T Clancy; H Spencer; S M Huson; F Lalloo
Journal:  Am J Med Genet A       Date:  2010-02       Impact factor: 2.802

9.  Single institution experience treating 104 vestibular schwannomas with fractionated stereotactic radiation therapy or stereotactic radiosurgery.

Authors:  Bethany M Anderson; Deepak Khuntia; Søren M Bentzen; Heather M Geye; Lori L Hayes; John S Kuo; Mustafa K Baskaya; Behnam Badie; Amar Basavatia; G Mark Pyle; Wolfgang A Tomé; Minesh P Mehta
Journal:  J Neurooncol       Date:  2013-10-20       Impact factor: 4.130

10.  Melanotic schwannoma of the acoustic nerve.

Authors:  R T Miller; H Sarikaya; A Sos
Journal:  Arch Pathol Lab Med       Date:  1986-02       Impact factor: 5.534

View more
  36 in total

1.  LINAC-based stereotactic radiosurgery versus hypofractionated stereotactic radiotherapy delivered in 3 or 5 fractions for vestibular schwannomas: comparative assessment from a single institution.

Authors:  Linn Söderlund Diaz; Andreas Hallqvist
Journal:  J Neurooncol       Date:  2020-02-08       Impact factor: 4.130

2.  Celastrol suppresses the growth of vestibular schwannoma in mice by promoting the degradation of β-catenin.

Authors:  Na Hui Kim; Minji Kwon; Jiwoo Jung; Hyo Byeong Chae; Jiwoo Lee; Yeo-Jun Yoon; In Seok Moon; Ho K Lee; Wan Namkung; Konstantina M Stankovic; Se A Lee; Jong Dae Lee; Sin-Aye Park
Journal:  Acta Pharmacol Sin       Date:  2022-04-27       Impact factor: 6.150

3.  Response prediction of vestibular schwannoma after gamma-knife radiosurgery using pretreatment dynamic contrast-enhanced MRI: a prospective study.

Authors:  Inpyeong Hwang; Seung Hong Choi; Jin Wook Kim; Eung Koo Yeon; Ji Ye Lee; Roh-Eul Yoo; Koung Mi Kang; Tae Jin Yun; Ji-Hoon Kim; Chul-Ho Sohn
Journal:  Eur Radiol       Date:  2022-01-27       Impact factor: 5.315

4.  Establishment of nomograms for the prediction of useful hearing loss in patients with neurofibromatosis type 2.

Authors:  Shi-Wei Li; Jing Zhang; Han-Lu Tang; Peng Li; Bo Wang; Fu Zhao; Pi-Nan Liu
Journal:  J Neurooncol       Date:  2021-11-09       Impact factor: 4.130

Review 5.  Evaluation of Vestibular Function in Diagnosis of Vestibular Schwannomas.

Authors:  Xue-Qing Zhang; Tai-Sheng Chen; Wei Wang
Journal:  Curr Med Sci       Date:  2021-08-17

Review 6.  Evaluating growth trends of residual sporadic vestibular schwannomas: a systematic review and meta-analysis.

Authors:  Abdullah Egiz; Hritik Nautiyal; Andrew F Alalade; Nihal Gurusinghe; Gareth Roberts
Journal:  J Neurooncol       Date:  2022-06-27       Impact factor: 4.506

7.  Stereotactic radiosurgery for Koos grade IV vestibular schwannoma in young patients: a multi-institutional study.

Authors:  Chloe Dumot; Stylianos Pikis; Georgios Mantziaris; Zhiyuan Xu; Rithika Kormath Anand; Ahmed M Nabeel; Darrah Sheehan; Kimball Sheehan; Wael A Reda; Sameh R Tawadros; Khaled Abdel Karim; Amr M N El-Shehaby; Reem M Emad Eldin; Selcuk Peker; Yavuz Samanci; Tehila Kaisman-Elbaz; Herwin Speckter; Wenceslao Hernández; Julio Isidor; Manjul Tripathi; Renu Madan; Brad E Zacharia; Lekhaj C Daggubati; Nuria Martínez Moreno; Roberto Martínez Álvarez; Anne-Marie Langlois; David Mathieu; Christopher P Deibert; Vivek R Sudhakar; Christopher P Cifarelli; Denisse Arteaga Icaza; Daniel T Cifarelli; Zhishuo Wei; Ajay Niranjan; Gene H Barnett; L Dade Lunsford; Greg N Bowden; Jason P Sheehan
Journal:  J Neurooncol       Date:  2022-09-27       Impact factor: 4.506

8.  A mechanistic mathematical model of initiation and malignant transformation in sporadic vestibular schwannoma.

Authors:  Chay Paterson; Ivana Bozic; Miriam J Smith; Xanthe Hoad; D Gareth R Evans
Journal:  Br J Cancer       Date:  2022-09-12       Impact factor: 9.075

Review 9.  Efficacy and comorbidities of hypofractionated and single-dose radiosurgery for vestibular schwannomas: a systematic review and meta-analysis.

Authors:  Umberto Tosi; Sergio Guadix; Anjile An; Drew Wright; Paul J Christos; Susan Pannullo; Andrew Brandmaier; Jonathan P S Knisely; Philip E Stieg; Rohan Ramakrishna
Journal:  Neurooncol Pract       Date:  2021-02-01

Review 10.  Outcomes of stereotactic radiosurgery for large vestibular schwannomas: a systematic review and meta-analysis.

Authors:  Umberto Tosi; Miguel E Tusa Lavieri; Anjile An; Omri Maayan; Sergio W Guadix; Antonio P DeRosa; Paul J Christos; Susan Pannullo; Philip E Stieg; Andrew Brandmaier; Jonathan P S Knisely; Rohan Ramakrishna
Journal:  Neurooncol Pract       Date:  2021-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.